Latest News for: cd137

Edit

Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral ...

Business Wire 19 Feb 2026
... data on ANK-203, a first-in-class anchored immunotherapy using monoclonal antibody CD137 (4-1BB).
Edit

Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO

Pharmiweb 18 Feb 2026
... anchored immunotherapy using monoclonal antibody CD137 (4-1BB) ... ANK-203 is designed to activate the CD137 (4-1BB) immune pathway through localized delivery and retention at the tumor site.
Edit

CD137 Targeted Therapy Research Report 2026-2030: Market Opportunities, Therapeutic Approaches, Technology Development Platforms & Clinical ...

Business Wire 31 Jan 2026
DUBLIN--(BUSINESS WIRE)--The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, ...
Edit

CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global ...

Nasdaq Globe Newswire 23 Jan 2026
Key market opportunities in CD137-targeted therapies include the upcoming commercial launch by 2030, robust clinical trial activity ...
Edit

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline and Competitive Intelligence Report 2025

Nasdaq Globe Newswire 27 Nov 2025
These therapies are in preclinical and clinical stages, targeting T cells and NK cells for cancer treatment ... .
  • 1

Article Search

tools
×
×
×
×